Background: Hyperprolactinemia is a common adverse reaction in patients with schizophrenia who take antipsychotic drugs; it often leads to treatment non-compliance in patients and has an adverse effect on their prognosis.
OBJECTIVE
The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia.
METHODS
One hundred and thirteen patients who were receiving a stable dose of risperidone were randomly assigned to either
OBJECTIVE
Accumulating evidence suggests that prolactin is a modulator of body weight and composition and that it regulates some transporters in adipose tissue. It was demonstrated that hyperprolactinemia is associated with weight gain and obesity. Ghrelin is a novel hormone secreted from many
Metformin was found to affect plasma levels of some pituitary hormones. This study was aimed at investigating whether metformin treatment has an impact on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance. The study included 27 patients
BACKGROUND
Elevated prolactin levels are associated with increased cardiometabolic risk. No previous study has compared the effect of hypolipidemic therapy on plasma levels of lipids and other cardiometabolic risk factors in patients with and without hyperprolactinemia.
METHODS
The study included
The effect of monomeric (glycosylated and unglycosylated) and dimeric form of porcine prolactin on change of the blood levels of triglycerides (TG) and cholesterol in lipoproteins (LP) of different density and the activity of the main enzymes of plasmatic and liver lipid metabolism were studied
Prolactin is a metabolic hormone. The hypothesis is that hyperprolactinemia can cause metabolic and inflammatory changes which are associated with accelerated atherosclerotic process, but the treatment of hyperprolactinemia with dopamine agonists, leads to reversibility of these processes. The first
In 3 groups of women (1. with pathological hyperprolactinemia, but low estradiol level--19 patients; 2. with pathological hyperprolactinemia, but high estradiol level--17 patients; 3. 16 healthy control women) the level of prolactin, estradiol, cortisol, total cholesterol, triglycerides and
Plasma total cholesterol (TC), triglycerides (TG), high-density lipoprotein-cholesterol (HDL-C), and low-density lipoprotein-cholesterol (LDL-C) were studied in 15 hyperprolactinemic women who had a prolactin (PRL) adenoma, in comparison to 15 age-matched control women. In the hyperprolactinemic
An endocrinopathy characterised by hyperprolactinaemia and galactorrhoea was found to be associated with primary hypothyroidism in an entire bitch. Clinical diagnosis was confirmed by lowered baseline T4 blood levels, reduced response to the thyroid stimulating hormone (TSH) test, elevated prolactin
The metabolic syndrome is a growing epidemic; it increases the risk for diabetes, cardiovascular disease, fatty liver, and several cancers. Several reports have indicated a link between hormonal imbalances and insulin resistance or obesity. Transgenic (TG) female mice overexpressing the human
BACKGROUND
Hyperprolactinemia and glucose and lipid metabolism abnormalities are often found in patients with schizophrenia and are generally considered secondary to the use of antipsychotic drugs. More recent studies have shown these same neuroendocrine and metabolic abnormalities in antipsychotic
OBJECTIVE
To determine whether men with hypogonadism are at risk for hyperlipidemia.
METHODS
Case-control study.
METHODS
Neuroendocrine clinical center of a referral-based university medical center.
METHODS
Consecutive sample of 18 men with testosterone deficiency who had prolactin-secreting
OBJECTIVE
Increasing evidence exists that hyperprolactinemia alters metabolic profile. The mechanism of this effect is unknown. We aimed to investigate the differences between the metabolic profile of patients with prolactinomas and nonfunctional pituitary adenomas and to evaluate the impact of